Fesoterodine

Fesoterodine

Systematic (IUPAC) name
[2-[(1R)-3-(Di(propan-2-yl)amino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate
Clinical data
Trade names	Toviaz
AHFS/Drugs.com	monograph
MedlinePlus	a609021
Licence data	EMA:Link, US FDA:link
Pregnancy category	US: C (Risk not ruled out)
Legal status	℞ (Prescription only)
Routes of administration	Oral
Pharmacokinetic data
Bioavailability	52% (active metabolite)
Protein binding	50% (active metabolite)
Metabolism	Hepatic (CYP2D6- and 3A4-mediated)
Biological half-life	7–8 hours (active metabolite)
Excretion	Renal (70%) and fecal (7%)
Identifiers
CAS Number	286930-03-8 N
ATC code	G04BD11 (WHO)
PubChem	CID: 6918558
IUPHAR/BPS	7473
DrugBank	DB06702 Y
ChemSpider	5293755 Y
UNII	621G617227 Y
KEGG	D07226 Y
ChEMBL	CHEMBL1201764 N
Chemical data
Formula	C26H37NO3
Molecular mass	411.278 g/mol
SMILES O=C(Oc1ccc(cc1[C@@H](c2ccccc2)CCN(C(C)C)C(C)C)CO)C(C)C
InChI InChI=1S/C26H37NO3/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3/t23-/m1/s1 Y Key:DCCSDBARQIPTGU-HSZRJFAPSA-N Y
NY (what is this?)  (verify)

Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB). It was approved by the European Medicines Agency in April 2007, the US Food and Drug Administration on October 31, 2008 and Health Canada on February 9, 2012.

Fesoterodine is a prodrug. It is broken down into its active metabolite, 5-hydroxymethyl tolterodine, by plasma esterases.

Efficacy

Fesoterodine has the advantage of allowing more flexible dosage than other muscarinic antagonists. Its tolerability and side effects are similar to other muscarinic antagonists and as a new drug seems unlikely to make great changes in practices of treatment for overactive bladder.